The antiepileptic drug vigabatrin has shown efficacy in the treatment of patients with refractory epilepsy. Unlike many other antiepileptics it is not bound to plasma protein and mainly eliminated by the kidney. Although the therapeutic and toxic serum concentration range is not clearly defined and efficacy and toxicity are not closely correlated with the dose, factors decreasing vigabatrin elimination such as advanced age or renal failure may pose risk of untoward effects. Thus far there are no dose recommendations available for patients on haemodialysis. We report on an epileptic patient who experienced severe, partially reversible renal failure as a consequence of near-drowning. In this patient serum concentrations of vigabatrin were measured repeatedly both during haemodialysis and after partial recovery of renal function. The terminal elimination half-life in this patient was 41 hours during the period of severe renal failure (creatinine clearance C5 ml/min). As about 60% of vigabatrin was removed from the blood pool by haemodialysis in these patients the antiepileptic should be administered after dialysis. To maintain serum concentrations in the usual range and to control seizure activity only 500 mg vigabatrin every 3 days were necessary.
INTRODUCTION
As the principal inhibitory neurotransmitter in the human brain, GABA is believed to play a major role in controlling seizure activity'. Vigabatrin is a new 'antiepileptic drug chemically related to gamma-aminobutyric acid (GABA)' which irreversibly inhibits inactivation of GABA by GABA-transaminase and thereby leads to accumulation of the transmitte?2.3. Oral treatment with vigabatrin produces dose-dependent increases in cerebrospinal fluid levels of GABA in manly4 and substantial decreases in seizure frequency in patients with refractory epilepsy'95*6. Possibly due to its mechanism of irreversible enzyme inhibition, no clear correlation between serum concentrations and clinical effects has been observed'*5. In patients successfully treated with the drug, serum concentrations between 8 and 278 pmol/l have been reported'>. Hence serum concentration monitoring is considered to be of very limited value in the treatment of patients with the compound. It may, however, be helpful, e.g. to distinguish non-responding from noncompliant patients.
Vigabatrin is supplied as a racemic mixture, with the S( +)-enantiomer possessing pharmacological activity and the R( -)-enantiomer being inactive*". After oral administration (R, S)-vigabatrin is rapidly absorbed reaching peak serum concentrations within 2 hours after dosine'.
Vigabatrin is not bound to plasma protein'. The apparent volume of distribution of (R, S)-vigabatrin is approximately 0.8 l/kg'. Vigabatrin exhibits linear pharmacokinetics with a half-life between 5.3 and 7.4 hours'*'. The major route of elimination is renal excretion of the unchanged compound'.
The pharmacokinetic 0 1996 British Epilepsy Association changes observed in elderly volunteers, attributed to the well known decrease in renal function with age, imply that dose reductions in elderly patients and in those with renal insufficiency are required to prevent toxicity". Thus far only limited information about the pharmacokinetics of vigabatrin in end-stage renal disease and during haemodialysis is published" and no dose recommendations for patients with severe renal failure are available. We report on a patient in whom serum concentrations of vigabattin were repeatedly measured at different levels of renal function as well as during haemodialysis and who required much lower maintenance doses than generally recommended for seizure control.
CASE REPORT
A 59-year-old male Caucasian who suffered from temporal lobe epilepsy with secondary generalized seizures since his childhood experienced an epileptic fit while he was walking along a river and fell into the river. He was rescued by two people witnessing the accident, successfully resuscitated, and admitted to the intensive care unit of our hospital.
Because of respiratory insufficiency he was intubated and mechanically ventilated.
During the respirator when midazolam was discontinued complex partial seizures became prominent again. For that reason antiepileptic treatment with vigabatrin was started.
As vigabatrin pharmacokinetics are not well characterized under the condition of haemodialysis, serum concentrations of (R, S)-vigabatrin were monitored during the first days of treatment before, during and after haemodialysis (Fig. 1) . Vigabatrin concentrations were determined by high-performance liquid chromatography using fluorescence detection as previously described'*. The limit of accurate detection was 1.5 pmol/l, the day-to-day coefficient of variation was 6.4% (n = 37, 43 pmol/l).
Three doses of vigabatrin (500 mg) were administered orally at daily intervals. During these initial days the patient underwent haemodialysis twice. Serum vigabatrin concentrations immediately before and at the end of the 4-hour dialysis were 49 and 20 pmolll after the first and 64 and 26 pmol/l after the second dialysis, respectively, indicating that approximately 60% of the serum pool were eliminated. After each dialysis serum concentrations increased suggesting the presence of a deep compartment and redistribution of vigabatrin during the hours following dialysis (Fig. 1) . The half-life calculated from the elimination phase after the second haemodialysis was 41 hours. Hence, to maintain serum vigabatrin concentrations in a range between 20 and 100 pmol/l it was enough to administer 500 mg vigabatrin every three days.
During the following weeks renal function gradually recovered to creatinine clearance values of 19 ml/minute at discharge of the patient. The calculated vigabatrin half-life during that period was 24 hours (Fig. 1) . Elimination rate constants calculated from the two elimination phases in our patient as well as from published figures for patients with moderate renal impairment"
were linearly related to renal function (creatinine clearance) and are shown in Fig. 2 .
Seizure activity: before administration of vigabatrin the patient had complex partial seizures once to twice a week with occasional secondary generalization. No epileptic fits were noted after discontinuation of midazolam within the first 30 days after onset of vigabatrin as long as serum concentrations were above 30 pmol/l. Two episodes of seizures were noted when renal function had improved (creatinine clearance 19 ml/min) both occurring on day 3 after dosing. For that reason the dosing interval was reduced to 500 mg every 2 days and the patient remained without seizures until discharge from the hospital 5 days later.
DISCUSSION
The central role of the kidney in the elimination of vigabatrin is well known and renal impairment has been incriminated for prolongations of the terminal half-life of the drug". Thus far there are no dose recommendations and only limited information available about the pharmacokinetics of vigabatrin in end-stage renal disease". The results in this patient on haemodialysis indicate that the terminal half-life of the drug may reach 41 hours, which is approximately 6 times longer than values observed in healthy volunteers'*9*'3. In this patient the elimination rate constants determined on two occasions were in good agreement with data extrapolated from the literature from patients with milder degrees of renal insufficiency. Compilation of the published figures with data of our patient with severe renal failure revealed the expected linear relationship between the vigabatrin elimination rate constant (ln2/half-life) and renal impairment. It is therefore likely that the prolongation of vigabatrin elimination is mainly due to changes in renal drug clearance and not the result of alterations in drug distribution.
Due to the markedly protracted elimination in this patient vigabatrin at a dose of 500mg every 3 days was sufficient to sustain serum concentrations in the usually observed range. As there is no close relationship between serum concentrations and antiepileptic effect is is important to emphasize that the dosing regimen in this patient was also successfully maintaining antiepileptic efficacy.
As expected for a small molecule not bound to proteins with a volume of distribution which is not excessively large, vigabatrin was substantially eliminated by a 4-hour haemodialysis. The amounts of drug removed in our patient are in accordance with data observed in another patient on dialysis .
l1 It is noteworthy that during haemodialysis the removal of large vigabatrin amounts from the body was not associated with the recurrence of epileptic fits. This may be explained by its mechanism of irreversible enzyme inhibition which is not acutely reversed by rapid withdrawal of the drug. Haemodialysis appears therefore safe even in patients on monotherapy with vigabatrin. However, as a substantial fraction of the blood is cleared within a single haemodialysis in these patients vigabatrin should preferentially be administered after dialysis.
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